source
- China biotech RiboX reveals first data of circular RNA therapies in peopleBiotech investors and pharma companies have poured billions into three Boston-region startups competing to develop a next-generation version of mRNA technology that could make for more durable and…Endpoints · 28m ago↗ source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…
- Researchers develop tumor "avatar" model that predicts immunotherapy response with 93% accuracy